Combination treatment benefits patients with advanced breast cancer that has spread to the brain

Patients with leptomeningeal metastasis (LM) have historically had few treatment options. Now, researchers from The University of Texas MD Anderson Cancer Center have found a combination of targeted therapies, tucatinib and trastuzumab, plus the chemotherapy drug, capecitabine, may improve symptoms and extend survival in some breast cancer patients with LM.

This article was originally published on MedicalXpress.com

You may also be interested in:

Read More:

Lawyers Lookup